Stock MYCOF MYDECINE INNOVATIONS GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mydecine Innovations Group Inc.

Equities

MYCOF

CA62849F2008

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 12:56:35 27/04/2024 am IST 		5-day change 1st Jan Change
0.0221 USD +72.58% Intraday chart for Mydecine Innovations Group Inc. +76.80% +48.32%
23/02 Mydecine Innovations Closes Partial Debt Settlement MT
02/02 Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 42.07 18.48 4.994 78.73 36.33 7.577
Enterprise Value (EV) 1 40.84 20.21 5.038 79.73 39.33 7.73
P/E ratio -2.27 x -1.08 x -0.95 x -1.88 x -1.13 x -0.44 x
Yield - - - - - -
Capitalization / Revenue - 8,89,80,106 x 1,80,43,776 x 1,34,59,62,065 x 4,84,83,14,108 x -
EV / Revenue - 9,73,10,385 x 1,82,03,373 x 1,36,31,53,038 x 5,24,95,60,605 x -
EV / EBITDA -2.66 x -3.66 x -1.57 x -6.68 x -1.76 x -0.48 x
EV / FCF -42.1 x -14.9 x -12.4 x -32 x -2.75 x -1.38 x
FCF Yield -2.37% -6.72% -8.08% -3.12% -36.4% -72.7%
Price to Book 43.9 x 5.5 x 0.5 x 22.1 x 172 x -2.41 x
Nbr of stocks (in thousands) 59.5 141 669 3,535 5,219 13,005
Reference price 2 707.5 131.3 7.468 22.27 6.961 0.5826
Announcement Date 30/04/18 30/04/19 02/06/20 30/04/21 31/03/22 31/03/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - 0.2077 0.2768 0.0585 0.007493 -
EBITDA 1 -15.33 -5.52 -3.201 -11.94 -22.31 -16.19
EBIT 1 -15.57 -5.542 -3.265 -12.05 -22.46 -16.28
Operating Margin - -2,668.81% -1,179.6% -20,598.75% -2,99,753.13% -
Earnings before Tax (EBT) 1 -17.56 -13.36 -3.508 -26.95 -23.58 -17.24
Net income 1 -17.56 -13.36 -3.508 -26.95 -28.9 -11.57
Net margin - -6,431.45% -1,267.37% -46,074.45% -3,85,658.6% -
EPS 2 -311.5 -122.1 -7.874 -11.85 -6.172 -1.338
Free Cash Flow 1 -0.9694 -1.359 -0.4069 -2.49 -14.3 -5.619
FCF margin - -654.35% -147.02% -4,256.3% -1,90,867.89% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 30/04/18 30/04/19 02/06/20 30/04/21 31/03/22 31/03/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales 0.00519 0.00007 -0.0138 - -
EBITDA - - - - -
EBIT - - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) -3.775 -4.537 -10.88 -5.638 -
Net income -3.775 -4.537 -10.88 -5.638 -
Net margin -72,731.6% -64,80,757.14% 78,906.38% - -
EPS 1 -1.000 -1.000 -2.000 -1.200 -0.3500
Dividend per Share - - - - -
Announcement Date 16/08/21 15/11/21 31/03/22 16/05/22 15/08/22
1CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - 1.73 0.04 1.01 3.01 0.15
Net Cash position 1 1.23 - - - - -
Leverage (Debt/EBITDA) - -0.3134 x -0.0138 x -0.0842 x -0.1348 x -0.009464 x
Free Cash Flow 1 -0.97 -1.36 -0.41 -2.49 -14.3 -5.62
ROE (net income / shareholders' equity) -1,362% -579% -52.4% -1,000% -1,250% 1,018%
ROA (Net income/ Total Assets) -358% -86.7% -26.4% -130% -164% -140%
Assets 1 4.899 15.41 13.3 20.74 17.61 8.233
Book Value Per Share 2 16.10 23.90 15.00 1.010 0.0400 -0.2400
Cash Flow per Share 2 30.50 0.0800 0.0300 0.6200 0.2900 0
Capex 1 0.1 0.01 - 0.29 0.29 -
Capex / Sales - 4.39% - 500.38% 3,890.32% -
Announcement Date 30/04/18 30/04/19 02/06/20 30/04/21 31/03/22 31/03/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MYDECINE INNOVATIONS GROUP INC. Stock Mydecine Innovations Group Inc.
+48.32% 1.36M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MYCOF Stock
  4. Financials Mydecine Innovations Group Inc.